Over the past decade, mesoporous silica nanoparticles (MSNs) smaller than 200 nm with a high colloidal stability have been extensively studied for systemic drug delivery. Although small molecule delivery via MSNs has been successful, the encapsulation of large therapeutic biomolecules, such as proteins or DNA, is limited due to small pore size of the conventional MSNs obtained by soft-templating. Here, we report the synthesis of mesoporous silica nanoparticles with extra-large pores (XL-MSNs) and their application to in vivo cytokine delivery for macrophage polarization. Uniform, size-controllable XL-MSNs with 30 nm extra-large pores were synthesized using organic additives and inorganic seed nanoparticles. XL-MSNs showed significantly higher loadings for the model proteins with different molecular weights compared to conventional small pore MSNs. XL-MSNs were used to deliver IL-4, which is an M2-polarizing cytokine and very quickly degraded in vivo, to macrophages and polarize them to anti-inflammatory M2 macrophages in vivo. XL-MSNs induced a low level of reactive oxygen species (ROS) production and no pro-inflammatory cytokines in bone marrow-derived macrophages (BMDMs) and in mice injected intravenously with XL-MSNs. We found that the injected XL-MSNs were targeted to phagocytic myeloid cells, such as neutrophils, monocytes, macrophages, and dendritic cells. Finally, we demonstrated that the injection of IL-4-loaded XL-MSNs successfully triggered M2 macrophage polarization in vivo, suggesting the clinical potential of XL-MSNs for modulating immune systems via targeted delivery of various cytokines.
Cancer
vaccine aims to invoke antitumor adaptive immune responses
to detect and eliminate tumors. However, the current dendritic cells
(DCs)-based cancer vaccines have several limitations that are mostly
derived from the ex vivo culture of patient DCs.
To circumvent the limitations, direct activation and maturation of
host DCs using antigen-carrying materials, without the need for isolation
of DCs from patients, are required. In this study, we demonstrate
the synthesis of extra-large pore mesoporous silica nanoparticles
(XL-MSNs) and their use as a prophylactic cancer vaccine through the
delivery of cancer antigen and danger signal to host DCs in the draining
lymph nodes. Extra-large pores of approximately 25 nm and additional
surface modification of XL-MSNs resulted in significantly higher loading
of antigen protein and toll-like receptor 9 (TLR9) agonist compared
with conventional small-pore MSNs. In vitro study
showed the enhanced activation and antigen presentation of DCs and
increased secretion of proinflammatory cytokines. In vivo study demonstrated efficient targeting of XL-MSNs co-delivering
antigen and TLR9 agonist to draining lymph nodes, induction of antigen-specific
cytotoxic T lymphocytes (CTLs), and suppression of tumor growth after
vaccination. Furthermore, significant prevention of tumor growth after
tumor rechallenge of the vaccinated tumor-free mice resulted, which
was supported by a high level of memory T cells. These findings suggest
that mesoporous silica nanoparticles with extra-large pores can be
used as an attractive platform for cancer vaccines.
Metallic nanoparticles (NPs) exhibit a localized surface plasmon resonance (LSPR) and act as scattering centers and subwavelength antennas, so metallic NPs can be incorporated into perovskite solar cells (PSCs) to effectively improve the light absorption of light harvesting devices. Here, we have embedded Au nanoparticles (NPs) into the hole transport layer (HTL) of the PSCs to investigate the photovoltaic effect of the PSCs with Au NPs. Interestingly, it was found that Au NPs dispersed spiro-OMeTAD HTL solution could naturally end up located near the perovskite layer as the result of the spin-coating step. Solar cell performance observations indicate that the LSPR and electrical effects of Au NPs enhance the photovoltaic response of PSCs, in spite of a slight decrease in the open-circuit voltage (VOC), by causing an incredible improvement in the photocurrent density as a dominant factor.
Excessive reactive oxygen species (ROS) play a significant role in the pathogenesis of many eye diseases. Controlling oxidative stress by reducing the amount of ROS is a potential therapeutic strategy for the prevention and treatment of eye diseases, particularly ocular surface diseases. Ceria nanoparticles (CeNPs) have been investigated owing to their efficient ROS-scavenging properties. To overcome the disadvantages of eyedrop administration due to rapid elimination on the surface of the eye and to retain the intrinsic properties of contact lenses, we developed an ROS-scavenging water-soluble CeNP-embedded contact lens (CeNP-CL) for the prevention of ocular surface diseases. The intrinsic ROS-scavenging property of the CeNPs, which mimicked the activities of superoxide dismutase and catalase, was incorporated into polyhydroxyethyl methacrylate-based contact lenses. The CeNP-CL exhibited high transparency and physical properties comparable to those of a commercial contact lens, along with excellent extracellular ROS-scavenging properties. The viabilities of human conjunctival epithelial cells and human meibomian gland epithelial cells were significantly enhanced in the presence of CeNP-CLs, even in media with high H 2 O 2 contents (100 and 500 μM). Additionally, the wearing of CeNP-CLs on the eyes had a protective effect in a mouse model when 3% H 2 O 2 eyedrops were administered. These results indicate the salvaging effect of the CeNP-CL in a high-ROS environment on the ocular surface, which may be helpful for the treatment of ocular surface diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.